Shire

Shire's drug for rare swelling disorder wins European panel green light
Shire's drug for rare swelling disorder wins European panel green light
Reuters
EMA
Europe
Shire
Takhzyro
HAE
Flag link:
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Fierce Pharma
Shire
FDA
Takeda
M&A
Flag link:
FDA advisers back Shire constipation drug
FDA advisers back Shire constipation drug
Pharmaforum
FDA
Shire
advisory panels
prucalopride
CIC
chronic idiopathic constipation
Flag link:
Shire opens $1B plant to make rare disease drugs
Shire opens $1B plant to make rare disease drugs
Fierce Pharma
Shire
Georgia
drug manufacturing
Flag link:
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
EP Vantage
Shire
Cinryze
Takhzyro
drug pricing
hereditary angiodema
Flag link:
Disgruntled Takeda alums demand a window into $62B Shire buy
Disgruntled Takeda alums demand a window into $62B Shire buy
Fierce Pharma
Takeda
Shire
M&A
Flag link:
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Bloomberg
Takeda
Shire
M&A
Xiidra
Flag link:
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Endpoints
Takeda
Shire
M&A
layoffs
Flag link:
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Endpoints
Takeda
Pharma CEOs
Christophe Weber
Shire
M&A
Flag link:
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
BioSpace
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
Flag link:
Shire Secures FDA Approval for HAE Drug Lanadelumab
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Flag link:
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Shire
Shionogi
ADHD
Japan
Intuniv
Flag link:
Takeda announces new series of non-core-asset sales
Takeda announces new series of non-core-asset sales
GoinPharma
Takeda
Shire
M&A
Flag link:
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Endpoints
Takeda
Shire
M&A
Flag link:
Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug
Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug
Endpoints
Oyster Point
OC-02
dry eye disease
Allergan
Restasis
Shire
Xiidra
Flag link:
FTC Clears Takeda's Acquisition of Shire
FTC Clears Takeda's Acquisition of Shire
CP Wire
FTC
M&A
Takeda
Shire
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Endpoints
Takeda
Shire
M&A
Japan
Flag link:
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
Reuters
Takeda
Shire
M&A
shareholders
Flag link:
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Fierce Pharma
CSL
HAE
Shire
Cinryze
Haegarda
Flag link:

Pages